BioCryst Pharmaceuticals 第二季財報會議重點摘要
· finance.yahoo.com
BioCryst Pharmaceuticals (NASDAQ:BCRX) 公布第二季財報，重點包括 ORLADEYO 營收成長、小兒口服顆粒劑型開始出貨，以及遺傳性血管性水腫（HAE）關鍵性 Navenibart 試驗完成受試者招募。總裁暨執行長 Charlie Gayer 表示...
BioCryst began shipping ORLADEYO oral pellets for pediatric patients during the week of the call. Gayer said the company had received 47 prescriptions through J...